Prognosis of inoperable patients after preoperative atezolizumab administration: A post hoc analysis of Lung Cancer Mutation Consortium (LCMC) 3

Lead Investigator: Kazuki Takada, Saiseikai Fukuoka General Hospital
Title of Proposal Research: Prognosis of inoperable patients after preoperative atezolizumab administration: A post hoc analysis of Lung Cancer Mutation Consortium (LCMC) 3
Vivli Data Request: 9911
Funding Source: None
Potential Conflicts of Interest: None

Summary of the Proposed Research:

Every year, about 2.2 million people find out they have lung cancer all over the world. It’s the number one cancer that causes people to die, affecting both men and women. There are two main types of lung cancer, but the one most people get is called non-small cell lung cancer (NSCLC). Sadly, when many people find out they have NSCLC, it’s already at a tough stage to treat, and their chances of getting better aren’t great. There’s a special medicine called immune checkpoint inhibitor (ICI), which has helped some people a lot before they have surgery to remove the cancer. But, there’s a chance it might make it so they can’t have their surgery as planned.

There was a study called Lung Cancer Mutation Consortium (LCMC) 3 that looked at how safe and effective a specific ICI, atezolizumab, is for people who can have surgery to remove their lung cancer. The study found that this medicine was safe and did a good job according to the main goal they were looking at, which is how much it could shrink the cancer before surgery. But, we don’t know much about what happens to people who can’t have surgery after taking the medicine or how other medicines they might be taking affect how well atezolizumab works.

The main goals of this study are to find out what happens to people who can’t have surgery after getting atezolizumab and how other medicines they take might make atezolizumab work better or worse.

To do this, we’re going to look back at the data from the LCMC3 study. We’ll compare two groups of people: those who had surgery and those who didn’t. We’re especially interested in how long people lived without their cancer getting worse and their overall survival. We’ll also look into why some people couldn’t have surgery, whether their cancer spread far or stayed close, and where it spread. We’re also curious about how taking other medicines might have played a role in how well the atezolizumab worked.

This study is important because it might help doctors figure out the best way to treat lung cancer that’s in a tough stage to treat, using medicines like atezolizumab before surgery.

Requested Studies:

A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients With Stage IB, II, IIIA, or Selected IIIB Resectable and Untreated Non-Small Cell Lung Cancer
Data Contributor: Roche
Study ID: NCT02927301
Sponsor ID: ML39236